Monophosphoryl Lipid A (S. enterica Minnesota, 595) (VAdv-Ly0011)
| CAT | Size | Price | Quantity | |
|---|---|---|---|---|
| VAdv-Ly0011 |
|
Monophosphoryl Lipid A, derivative from S. enterica Minnesota, 595, a TLR4-based vaccine adjuvant.
Datasheet
Specifications
Type
Lipopolysaccharide
Formula
Monophosphoryl Lipid A from S. minnesota R595
Product Form
White powder
Storage
Store at -20°C.
Shelf Life
1 year
Adjuvant Information
Introduction
Monophosphoryl lipid A (MPLA) is a TLR4 agonist and derivative of lipid A from Salmonella minnesota R595 lipopolysaccharide. Compared with the lipid A region of lipopolysaccharide (LPS), it is a low-toxicity derivative. When tested in animal models as a vaccine adjuvant, MPLA induces a strong Th1 response. MPLA is attributed to the preferential recruitment of TRIF upon TLR4 activation, resulting in decreased induction of inflammatory cytokines. While the toxicity associated with LPS prohibits its potential clinical use, MPLA is being developed as a vaccine adjuvant. It has been used extensively in clinical trials as a component in prophylactic and therapeutic vaccines targeting infectious disease, cancer and allergies.
Related Product
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
